CG MEDTECH, DIAGNOSTICS AND DIGITAL HEALTH & SERVICES FORUM - MIMEDX GROUP INC

Financial Performance:

• Reported Q3 net sales of $62 million, with the surgical franchise accounting for two-thirds of revenue and growing 9% in dollars (mid-teens in volume) year-over-year.
• Matured wound franchise faced headwinds from 2026 Medicare reimbursement reforms but showed promising signs of market share gain despite challenging comparisons.
• Achieved positive adjusted EBITDA and positive free cash flow in Q3 following infrastructure right-sizing efforts.
• Maintained a robust balance sheet with $121 million in cash, zero debt, and a structural gross margin of 80%.
• Secured a $25 million structured settlement from a wound care competitor regarding IP infringement.

Guidance and Future Outlook:

• Aims to complete the acquisition of Sonara MedTech pending FTC approval, targeting a combined $400 million top-line company by the first year post-closing.
• Forecasts the combined entity to derive approximately 75% of revenue from the surgical sector with adjusted EBITDA margins exceeding 20%.
• Believes the 2026 Medicare reimbursement reforms will remain status quo for 2027 under the new PFS and OPPS rates.
• Plans to accelerate growth by shifting product mix toward surgical offerings and leveraging a pipeline of new product launches, including two 510K FDA submissions.
• Anticipates the release of an RCT for the EpiEffect wound product later in the year.

Business Segments and Product Lines:

• Surgical Franchise: Represents the primary growth engine (approx. $40M in Q3), driven by double-digit volume growth and evidence-based outcomes (e.g., AmnioFix grafts reducing anastomotic leak rates by ~50% in GI surgery).
• Wound Care: Facing temporary disruption from reimbursement shifts; strategy focuses on patient migration to wound care centers and maintaining leadership through clinical evidence and a vertically integrated tissue supply network.
• Sonara Acquisition: Adds a 100% operating-room-focused portfolio with >$100M in revenue, featuring differentiated no-rinse irrigation and bone fixation products, alongside access to hundreds of third-party agents.
• Inorganic Growth: Recent additions include Heliogen and G for Derm Plus to the surgical lineup.

Market and Competitive Landscape:

• Addresses a Total Addressable Market (TAM) of nearly 100 million U.S. surgical procedures annually, aspiring to capture a portion of all subspecialties.
• Identifies a $4 billion incremental addressable market unlocked via Sonara, specifically in no-rinse irrigation and bone fixation.
• Leverages a competitive moat consisting of broad IP, a mature supply chain, extensive commercial reach, and leading payer coverage.
• Positioned as the largest dedicated regenerative medicine company post-combination, differentiating through the "Prepare, Promote, Protect" framework to increase share of wallet within single procedures.

Risks and Challenges:

• Medicare reimbursement reforms in 2026 created a "clumsy" reset in the wound care market, leading to non-linear recovery and reduced spending.
• Pending regulatory approval from the Federal Trade Commission (FTC) regarding the Sonara acquisition, which has issued a second request.
• Ongoing litigation risks, though mitigated by recent favorable court rulings and IP infringement settlements.
• Potential market volatility or slow recovery in the wound care sector despite structural improvements.

Management Commentary and Tone:

• Management expresses a "bullish" and confident tone, emphasizing a return to profitability and a "singular focus" on regenerative medicine.
• CFO Doug Rice highlighted strong financial discipline, noting the successful transition from a legacy business to a surgical-led growth story.
• Emphasized the strategic alignment of the Sonara deal in accelerating the goal of becoming a $400M surgical-led company.
• Stressed that the company has "weathered the storm" in wound care and is forging ahead from a position of strength with cash generation and committed financing.

Analyst Questions and Answers:

• Question: How has the strategy shifted in response to the 2026 Medicare reimbursement overhaul in the wound care sector?
• Answer: The company reorganized earlier in the year to align with the new market dynamics, successfully driving patient migration to wound care centers and maintaining year-over-year volume growth in that setting; no further strategic changes are anticipated for the upcoming year.

Other Key Points:

• The company is leveraging a "five-pillar" investment rationale: large market opportunity, strong competitive moat, Sonara acquisition, experienced leadership team, and a strong balance sheet.
• CEO Joe Capper has identified two "North Star" priorities: continuous innovation across platforms and shifting the revenue mix toward the more durable surgical sector.
• MiMedx has a vertically integrated supply chain starting from C-section deliveries through donor recovery to processing.
• The Sonara acquisition is viewed as an accelerator for both revenue growth and financial profile, with the team confirming a strong cultural fit.